arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

4D Molecular Therapeutics, Inc.

FDMT

$10.77 ▲ +0.22 (+2.09%) at close

8 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

4D Molecular Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $623.9M

Dividend Yield —

Revenue Growth 230194.6% ↗

Op. Margin -187.2%

ROIC -24.9% ↗

FCF / Share $-1.89 ↗

Trailing P/E —

Price / Book 1.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$85.21M

↑ +230194.6% —

Net Income Profit after all expenses

$-140.11M

↑ +12.9% —

Operating Margin Operating profit as % of sales

-187.2%

↑ +52.7% 0th

FCF / Share Free cash flow per share

$-1.89

↑ +26.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	230194.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2877332%)	-99.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1348%)	562.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+6929%)	-82.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1133%)	32.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+306%)	94.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1086%)	—	—
EPS Growth YoY (%)	18.8% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-15.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	22.3% Good Good Year-over-year change in earnings per share Optimal: > 10%	-29.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	12.9% Fair ↑ Fair Improving Year-over-year change in net income	-59.5% Weak ↓ Weak Declining Year-over-year change in net income	6.2% Fair ↑ Fair Improving Year-over-year change in net income	-50.7% Weak ↓ Weak Declining Year-over-year change in net income	-25.8% Weak Weak Year-over-year change in net income	-15.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	26.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-27.8% Weak ↓ Weak Declining Year-over-year change in free cash flow	33.9% Excellent Excellent Year-over-year change in free cash flow	-7.6% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	200.9% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-87.3% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	15.0% Excellent Excellent Compound annual revenue growth over 3 years	-23.5% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	44.3% Excellent Excellent Compound annual revenue growth over 5 years	-64.9% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	-187.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1348%)	—	—	—	-395.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2736%)	-416.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2875%)	—	—
Profit Margin (%) (%)	-164.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1470%)	—	-486.6% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4155%)	—	-395.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3395%)	-416.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3571%)	—	—
FCF Margin (%) (%)	-128.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-379.1% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	—	-433.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-381.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-24.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-29.1% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-29.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-37.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	55.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-28.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-33.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-20.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-87.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-27.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-285%)	-31.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-310%)	-32.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-318%)	-46.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-410%)	-22.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-249%)	-22.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-247%)	67.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+350%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-60.24M	$-149.34M	$-249.11M	$-52.35M	$-153.00M	$-276.73M	$-49.65M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$1.47	$0.00	$0.53	$0.10	$0.65	—	—	—
Basic EPS, GAAP (USD)	$-2.42	$-2.98	$-2.58	$-3.32	$-2.57	—	—	—
Free Cash Flow per Share (USD)	$-1.89	$-2.57	$-2.01	$-3.04	$-2.82	—	—	—
Book Value per Share (USD)	$8.78	$11.15	$7.15	$7.09	$9.90	$9.61	$-14.09	—
Tangible Book Value per Share (USD)	$8.78	$11.15	$7.15	$7.09	$9.90	$9.61	$-14.09	—
Basic Weighted Avg Shares (shares)	57.93M	53.94M	39.13M	32.35M	27.73M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$369.15M	$405.78M	$277.64M	$204.78M	$239.94M	$265.91M	$39.55M	—
Total Equity (USD)	$505.66M	$510.61M	$307.83M	$231.34M	$319.11M	$256.39M	$-72.97M	$-27.59M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$85.21M	$37.00K	$20.72M	$3.13M	$18.04M	$13.61M	$6.99M	—
Depreciation Expense (USD)	$5.20M	$4.80M	$4.40M	$2.40M	$1.50M	$1.40M	$1.00M	—
Net Income, GAAP (USD)	$-140.11M	$-160.87M	$-100.84M	$-107.49M	$-71.32M	$-56.69M	$-49.31M	—
Operating Cash Flow (USD)	$-109.08M	$-134.59M	$-75.79M	$-86.69M	$-69.13M	$-50.91M	$-36.71M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters

4D Molecular Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare FDMT with peers